Can the Novacyt (NCYT) share price make a comeback?

The Novacyt (NCYT) share price has had a rough year, falling by nearly 60% since January. But is it about to make a comeback? Zaven Boyrazian investigates.

| More on:

The content of this article was relevant at the time of publishing. Circumstances change continuously and caution should therefore be exercised when relying upon any content contained within this article.

Woman sneaker shoe and Arrow on street with copy space background

Image source: Getty Images

When investing, your capital is at risk. The value of your investments can go down as well as up and you may get back less than you put in.

Read More

The content of this article is provided for information purposes only and is not intended to be, nor does it constitute, any form of personal advice. Investments in a currency other than sterling are exposed to currency exchange risk. Currency exchange rates are constantly changing, which may affect the value of the investment in sterling terms. You could lose money in sterling even if the stock price rises in the currency of origin. Stocks listed on overseas exchanges may be subject to additional dealing and exchange rate charges, and may have other tax implications, and may not provide the same, or any, regulatory protection as in the UK.

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More.

2021 has not been kind to the Novacyt (LSE:NCYT) share price. Despite rising from 14p at the start of 2020, all the way to 852p by the end of the year, it has since collapsed to around 350p today. While the stock price has still increased by over 50% over the past 12 months, it’s firmly below its 2020 end-of-year high. But is that about to change? Let’s take a look.

The volatile Novacyt share price

I’ve previously explored this business. But as a quick reminder, Novacyt is a medical diagnostics firm that develops and sells pathogen testing kits for the medical, biotech, and food sectors.

When Covid-19 reared its head, the firm’s management team quickly switched its focus to creating a rapid testing kit to help track the spread of the virus. This move turned out to be an excellent decision. Novacyt became the first company to bring a Covid-19 testing kit to the market – enjoying a temporary mini-monopoly in the process. In fact, this is precisely why the NCYT share price exploded last year.

Unfortunately, this upward momentum quickly reversed. A rising tide of uncertainty started brewing among investors regarding how this business would function in a post-pandemic world. Novacyt does have an extensive portfolio of non-Covid-related products. But the level of sales doesn’t come close.

Then in April this year, the worst happened. In a single decision by the Department of Health & Social Care (DHSC), the supply contract between it and Novacyt was terminated – eliminating around half of Novacyt’s Covid-19 testing kit revenue in the process. This devastating blow to the business saw the NCYT share price crash by around 40% within 24 hours.

The Novacyt NCYT share price has is risks

New revenue on the horizon

The loss of the DHSC contract is disappointing. And while the management team is pursuing legal action to reinstate the agreement, I’m sceptical of the matter being resolved any time soon. But this ultimately may not matter.

Why? Because at the start of June, the company announced it had just launched two new Covid-19 testing kits – one of which has piqued my interest and may be able to propel the NCYT share price once again. The first is a three-gene assay test that allows the business to expand its reach into the travel market since it can be used to quickly verify fit-to-fly certificates. The second is more complex. It is the first single testing kit brought to market that can identify the Indian, South African, and Brazilian variants of Covid-19.

In 2020, Novacyt proved the power of being first, especially when it comes to products in exceptionally high demand. These latest product launches might be sufficient to recover the lost DHSC revenue by expanding its existing pool of private clients, and may even lead to new public sector supply contracts.

The bottom line

The progress made this year by the management team is encouraging. At least, I think so. And if these latest products prove to be as lucrative as the business hopes, the NCYT share price could be on the verge of making an explosive comeback.

Having said that, there remain a lot of unknowns. The good news might come to nothing and at this stage, all I can do is speculate. Therefore, Novacyt is staying on my watch list until more information is available.

Should you invest, the value of your investment may rise or fall and your capital is at risk. Before investing, your individual circumstances should be assessed. Consider taking independent financial advice.

Zaven Boyrazian does not own shares in Novacyt. The Motley Fool UK has no position in any of the shares mentioned. Views expressed on the companies mentioned in this article are those of the writer and therefore may differ from the official recommendations we make in our subscription services such as Share Advisor, Hidden Winners and Pro. Here at The Motley Fool we believe that considering a diverse range of insights makes us better investors.

More on Investing Articles

Investing Articles

Are these the best stocks to buy on the FTSE right now?

With the UK stock market on the way to hitting new highs, this Fool is considering which are the best…

Read more »

Petrochemical engineer working at night with digital tablet inside oil and gas refinery plant
Investing Articles

Can the Centrica dividend keep on growing?

Christopher Ruane considers some positive factors that might see continued growth in the Centrica dividend -- as well as some…

Read more »

Smiling family of four enjoying breakfast at sunrise while camping
Investing Articles

How I’d turn my £12,000 of savings into passive income of £1,275 a month

This Fool is considering a strategy that he believes can help him achieve a stable passive income stream with a…

Read more »

Person holding magnifying glass over important document, reading the small print
Investing Articles

2 top FTSE 250 investment trusts trading at attractive discounts!

This pair of discounted FTSE 250 trusts appear to be on sale right now. Here's why I'd scoop up their…

Read more »

Smiling young man sitting in cafe and checking messages, with his laptop in front of him.
Investing Articles

3 things that could push the Lloyds share price to 60p and beyond

The Lloyds share price has broken through 50p. Next step 60p? And then what? Here are some thoughts on what…

Read more »

Young female business analyst looking at a graph chart while working from home
Investing Articles

£1,000 in Rolls-Royce shares a year ago would be worth this much now

Rolls-Royce shares have posted one of the best stock market gains of the past 12 months. But what might the…

Read more »

Investing Articles

Are HSBC shares a FTSE bargain? Here’s what the charts say!

There are plenty of dirt-cheap FTSE 100 banking stocks for investors to choose from today. Our writer Royston Wild believes…

Read more »

Three signposts pointing in different directions, with 'Buy' 'Sell' and 'Hold' on
Investing Articles

Just released: Share Advisor’s latest ‘Hold’ recommendation [PREMIUM PICKS]

In our Share Advisor newsletter service, we provide buy, sell, and hold guidance for our universe of recommendations.

Read more »